#Roche
Roche今日宣布收购Tusk Therapeutics
首付款7,000万欧元现金
里程碑款项可能高达5.85亿欧元
Tusk成立于2014年
旗下有两款即将进入临床产品
Anti-CD25抗体和Anti-CD38抗体
其中
Anti-CD25抗体
旨在清除调节性T抗体
来增强和/或恢复抗肿瘤免疫力
可单药也可以联合PD-(L)1应用
为2017年自UCL&CRUK引进产品
预计将于明年进入临床
另一款产品为
Anti-CD38抗体
则也是给予厚望产品
可以激活CD8+和CD4+T细胞
从而直接或者间接起到
杀死肿瘤细胞和抑制免疫抑制的作用
与JNJ旗下同样靶向CD38的Daratumumab不同的是
该抗体靶向CD38抗原不同的表位
目前多发性骨髓瘤进展顺利
今年下半年将进军实体瘤临床
Stevenage, United Kingdom – September 28th 2018: Tusk Therapeutics Ltd (“Tusk”) was today acquired by Roche. Tusk has developed an antibody with a novel mode of action aimed at depleting regulatory T-cells (Tregs). Tregs suppress immune responses, including those against cancer cells. Preclinical data has shown that depleting Tregs from the tumor microenvironment can enhance and/or restore anti-tumor immunity. Tusk’s antibody has been designed to deplete these harmful Tregs, while not interfering with other immune cells acting against the tumor. Tusk’s program is expected to start clinical trials in cancer patients towards the end of 2019.
Tusk was founded in 2014 by Droia Oncology Ventures, Tusk’s majority shareholder. Under the terms of the agreement, Tusk’s shareholders will receive an upfront cash payment of Euro 70 million, plus additional contingent payments of up to Euro 585 million based on achievements of certain predetermined milestones.
Luc Dochez, Chief Executive Officer of Tusk Therapeutics, said: “We are delighted that Roche will further develop this novel antibody and drive the development ahead. The remaining portfolio of our immune-oncology targets will be further developed by Black Belt Therapeutics, a newly formed company spun out of Tusk Therapeutics.”